Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pasithea Therapeutics Corp. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
KTTA
Nasdaq
2830
www.pasithea.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pasithea Therapeutics Corp.
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
- Feb 5th, 2025 11:59 am
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
- Jan 14th, 2025 1:02 pm
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Sep 26th, 2024 10:44 pm
Sector Update: Health Care Stocks Mixed Late Afternoon
- Sep 26th, 2024 7:58 pm
Top Midday Gainers
- Sep 26th, 2024 5:49 pm
Why Is Pasithea Therapeutics Stock Surging On Thursday?
- Sep 26th, 2024 12:56 pm
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
- Sep 26th, 2024 11:02 am
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
- Sep 9th, 2024 12:01 pm
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
- Sep 3rd, 2024 12:02 pm
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Aug 28th, 2024 1:11 pm
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
- Jun 13th, 2024 10:59 am
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
- May 28th, 2024 10:59 am
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
- Apr 29th, 2024 11:59 am
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
- Apr 24th, 2024 11:59 am
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
- Feb 13th, 2024 12:59 pm
Scroll